Announcements Trials

Browse Landscape

Status

Completed 97 Terminated 26 Recruiting 23 Active not recruiting 14 Unknown 9 Withdrawn 5 Not yet recruiting 5 Suspended 2 No longer available 2 Enrolling by invitation 2 Available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 7 Carcinoma, Non-Small-Cell Lung 7 Sarcoma 5 Pancreatic Neoplasms 5 Multiple Myeloma 5 Melanoma 5 Prostatic Neoplasms 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Ovarian Neoplasms 3 Lymphoma, Large B-Cell, Diffuse 3 Leukemia, Myeloid, Acute 3 Glioblastoma 3 Breast Neoplasms 3 Urinary Bladder Neoplasms 2 Stomach Neoplasms 2 Small Cell Lung Carcinoma 2 Recurrence 2 Primary Myelofibrosis 2 Non-Muscle Invasive Bladder Neoplasms 2 Neuroblastoma 2 Neoplasm Metastasis 2 Lymphoma, T-Cell, Peripheral 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Follicular 2 Lymphoma 2 Head and Neck Neoplasms 2 Gastrointestinal Neoplasms 2 Colorectal Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Transitional Cell 2

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Available × INDUSTRY × Adenocarcinoma × Clear all

NCT06048081 2025-09-10

Early Access Program for Zolbetuximab

Astellas Pharma Inc

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡